# US 2013/0252986 A1 · Compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0252986 A1
- Document ID: US20130252986A1
- Status: Published application
- Kind: A1
- Application number: 13/991,953
- Filed: 2011-12-05
- Published: 2013-09-26
- Earliest claimed: 2010-12-06
- Assignees: Glaxo Group Limited
- Inventors: Zehong Wan; Xiaomin Zhang; Jian Wang; Cheng Peng; Yun Jin; Yimin Hu
- Web page: https://patentgrep.com/patent/US20130252986A1

## CPC

- C07D 239/52: Two oxygen atoms
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 213/69: Two or more oxygen atoms
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease and/or diabetic macular edema.

## Claims

### Claim 1

A compound of Formula (I) or a pharmaceutically acceptable salt thereof
wherein:
A is N or CH;
n is 1 or 2;
when A is N, Y Is absent, O or CH2 or when A is CH, Y is O;
Z is H, C1-C3 Alkyl; —(C1-C3alkyl)-heteroaryl wherein said heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of C1-C3 alkyl and C1-C3alkoxyl;
Ra is H, F, Cl, or C1-C3alkyl;
Rb is phenyl or heteroaryl either of which is optionally substituted with one or more substituents independently selected from the group consisting of CN and halo; and
Rc is phenyl or heteroaryl, wherein either of phenyl or heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of halo, C1-C3alkyl, and C1-C3haloalkyl.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein A is N.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein n is 1 or 2.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein X is O.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein Y is O.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein z is —CH2— heteroaryl, wherein said heteroaryl is selected from the group consisting of pyridinyl, pyrazole, pynmidinyl, and the heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of CH2 and —OCH3.

### Claim 7 (depends on 1)

The compound according to claim 1, wherein Ra is H.

### Claim 8 (depends on 1)

The compound according to claim 1, wherein Rb is phenyl optionally substituted with one or more substituents independently selected from the group consisting of CN and F.

### Claim 9 (depends on 1)

The compound according to claim 1, wherein Rc is phenyl optionally substituted with one or more substituents independently selected from the group consisting of F, Cl, CH3 or CF3.

### Claim 10 (depends on 1)

The compound according to claim 1, wherein
A is n;
n is 1 or 2;
x is O;
Y is O:
Z is —CH2-heteroaryl, wherein, said heteroaryl is selected from the group consisting of pyrodinyl, pyrazole, pyrimidyl, and the heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of CH2 and —OCH3;
Ra is H, F or Cl;
Rb is phenyl optionally substituted with one or more substituents independently selected from the group consisting of CN and F; and
Rc is phenyl optionally substituted with one or more substituents independently selected from the group consisting of F, Cl, CH3 and CF3.

### Claim 11 (depends on 1)

A pharmaceutical composition, comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1 and a pharmaceutically acceptable carrier.

### Claim 12 (depends on 1)

A method for treating Alzheimer's disease in a subject Comprising to a subject in need thereof a safe and effective amount of a Compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1.

### Claim 13 (depends on 1)

A method for treating atherosclerosis in a subject comprising administering to a subject in need thereof a safe and effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof according to claim 1.

### Claim at position 14

14-15. (canceled)
